research

Several renowned scientists working on multiple sclerosis (MS) recently joined forces to discuss and highlight the progress and knowledge gaps related to MS research, the prospects of finding a cure for the disease, and a strategy to reduce the burden the disease places on patients. A series of articles was published by the researchers in the…

Phoenix, Arizona-based Creative Medical Health (CMH) has just announced it has submitted a patent application for its proprietary mesenchymal stem cell pipeline product, indicated for autoimmune diseases. The company is already preparing to launch the product into its first line of clinical tests, which will…

Acorda Therapeutics, Inc. has released results from a Phase 1 clinical trial of rHIgM22 for multiple sclerosis, showing that the medication is safe and produces few side effects. rHIgM22 is a medication that may induce the re-wrapping of the myelin sheath that surround nerve cells,…

MicroConstants China, Inc., a company that provides preclinical, clinical, and consulting services to biotechnology and pharmaceutical companies, has just announced it has acquired international rights to the development of AA98 antibody pipeline products, indicated for the treatment of several types of cancer, multiple sclerosis, and age related macular degeneration…

Drug development company Rock Creek Pharmaceuticals, Inc. recently announced that a new clinical trial application with the United Kingdom’s Medicines Healthcare Products Regulatory Agency (MHRA) has been approved. The company is set to proceed with a Phase I study of its flagship pipeline product, Anatabine Citrate, a chemical that is found naturally…

A new study on the association between Helicobacter pylori and multiple sclerosis (MS) entitled “Helicobacter pylori infection as a protective factor against multiple sclerosis risk in females” was published in the Journal of Neurology, Neurosurgery & Psychiatry by Marzena J. Fabis Pedrini from the Centre…

A report by Bloomberg News‘ Caroline Chen says multinational biotech firm Biogen Idec Inc. is teaming up with Internet and IT colossus Google, pooling efforts to research environmental and biological factors potentially associated with Multiple Sclerosis (MS) progression. Ms. Chen notes that the Biogen Idec relationship is…

Teva Pharmaceutical Industries Ltd. recently made a major announcement on the U.S. Supreme Court‘s ruling on the matter of “Teva Pharmaceuticals USA, Inc. et al. Petitioners v. Sandoz Inc. et al. that reversed the Federal Circuit Court’s judgment of invalidity…

A study from a team of researchers at the Kessler Foundation provides new findings on multiple sclerosis (MS). According to the study, published in the journal Frontiers in Neurology, cognitive fatigue exhibited by MS patients is related to the length of the task they are involved in. Fatigue…

A new research study indicates that in patients with relapsing-remitting multiple sclerosis (MS), treatment with nonmyeloablative hematopoietic stem cell transplantation leads to improvement in neurological impairment and quality of life. The study, entitled “Association of Nonmyeloablative Hematopoietic Stem Cell Transplantation With Neurological Disability in Patients With Relapsing-Remitting Multiple…

Biopharmaceutical company Receptos, Inc. has enrolled the first participant with relapsing multiple sclerosis (RMS) in its SUNBEAM phase 3 trial, which will evaluate the potential therapy RPC1063 in patients who suffer from the disease. The company’s phase 3 RADIANCE trial, also…

Amarantus BioScience Holdings, Inc. has announced the acquisition of DioGenix, Inc., which will be merged as a new foundational asset into a growing neuro-diagnostic division at Amarantus called Amarantus Diagnostics. Amarantus BioScience is dedicated to developing novel neurological diagnostic tests and therapy options in the fields of neurology, psychiatry, ophthalmology and regenerative diseases, including multiple…

Arena Pharmaceuticals, Inc. released the first results from its phase 1b trial that for the evaluation of an oral drug candidate called APD334 for the treatment of autoimmune diseases, such as multiple sclerosis (MS). The multiple ascending dose clinical trial demonstrated encouraging findings about the drug, which is designed to target the sphingosine…

Multiple sclerosis (MS) patients often experience difficulty with balance and fear falling, which may prevent them from being social or participating in exercise and community activities, affecting their quality of life. However, a pioneering study conducted at the University of Massachusetts Amherst is looking to understand the role of…

Biogen Idec, a Cambridge Massachusetts Biotechnology company, has released results from its Phase 2 acute optic neuritis (AON) RENEW trial. The trial tested anti-LINGO-1, a medication that restores myelin — a fatty substance that facilitates nerve cell impulses by wrapping around them and providing insulation. The trial results indicate that anti-LINGO-1…

California-based, late-preclinical stage pharmaceutical company, Bionure, Inc,. has just announced it has signed a Sponsored Research Agreement with the National Multiple Sclerosis Society, thanks to Fast Forward, a division of the Society dedicated to commercial research and development for novel solutions for multiple sclerosis (MS). According…

Human papillomavirus (HPV) vaccination can help protect against several health problems, including cervical cancers in women. Some reports have raised concerns however, that the vaccine might actually increase the risk of developing multiple sclerosis. A study entitled “Quadrivalent HPV Vaccination and Risk of Multiple Sclerosis and Other…

A new study published online before print in the journal JAMA Neurology reports that three years on, most members of a small subject group of patients with active relapsing-remitting (RR) multiple sclerosis (MS) who had received an experimental high-dose immunosuppressive therapy (HDIT) followed by a transplant of their own…

Given the fact that MS is a chronic, progressive, and disabling disease for which there is no cure, the multiple sclerosis community is always looking forward to the latest news regarding new therapies, devices or scientific findings about treating and curing the disease. These are the top 14 news stories of 2014 from…

A team of researchers from Italy recently examined if p53 genetic variants influence synaptic and toxic effects of cytokines in the neurodegenerative processes that occurs in Multiple Sclerosis. The study, entitled “Interleukin-1β causes excitotoxic neurodegeneration and multiple sclerosis disease progression by activating the apoptotic protein p53,” was recently published…

A study published on December 22 in JAMA Neurology emphasizes that a standard measurement used to gauge multiple sclerosis (MS) symptoms, known as “no-evidence-of-disease-activity” (NEDA) is important for determining how the disease will progress long-term. MS is the most common degenerative neurological condition that affects young adults worldwide.

Researchers in Spain have found that specific fat stem cells from mice could be excellent tools for studying transplantation of stem cells in autoimmune diseases, such as multiple sclerosis (MS). The work was published in the December 12th issue of the journal, Stem Cell Research & Therapy. The…

Icometrix, a biotechnology company focused on unique projects for diagnosing and treating multiple sclerosis (MS) patients, has designed new software for the measurement of brain lesions and brain volumes and their changes over time. MS, a chronic and neurological condition that affects about 2.5 million people throughout the world, is often first detected in patients at…

Mapi Pharma Ltd., a development stage pharmaceutical company specializing in the development of high-barrier to entry and high-added value generic drugs, announced it has treated the first patient in the Phase IIa study of GA Depot for relapsing-remitting multiple sclerosis (RRMS). Lead investigator Professor Ariel Miller, M.D., Ph.D., Head of the Multiple Sclerosis & Brain…

A new study on the development of therapeutic monoclonal antibodies to treat neuroinflammatory and demyelinating disease entitled “SEMA4D compromises blood–brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease” was published in the journal Neurobiology of Disease by Ernest S. Smith part of…

A new Multiple Sclerosis pilot study was awarded a $39,000 grant by the National Multiple Sclerosis Society to investigate how patients’ sensation in their feet while standing impacts balance and whether their ability to walk is improved through the use of vibrating insoles. Multiple Sclerosis is characterized by the destruction of the…

In a new study, researchers based at the Imperial College, London will follow in unprecedented detail the events and experiences in lives of people with multiple sclerosis (MS) in order to improve evaluation protocols for MS treatments. MS is estimated to afflict more than two million people globally, more…

A team of researchers from Ohio State University received a $44,000 grant from the National Multiple Sclerosis Society to fund the development and testing of an interactive video game designed to promote and supplement physical therapy among patients suffering from multiple sclerosis (MS), an…

Researchers have uncovered new information about myelin, a fatty substance that wraps around the axons of brain cells (neurons) allowing them to transmit information quickly from one cell to another. De-myelinating diseases in which the insulating wrap is damaged include multiple sclerosis, in which unpredictable loss of myelin causes…

2014 was a year of major progress in research for treating and curing multiple sclerosis (MS), according to the National Multiple Sclerosis Society. This year the National Multiple Sclerosis Society reports that the organization invested over $50 million into 380 new and ongoing research initiatives and projects for MS. The Society remains highly…